DrugApproved

Insulin icodec

insulin icodec

Long-acting insulin analogue injected once a week. US FDA approved it for adults with type 2 diabetes in 2026 and, per FDA notice of 23 October 2026, for children aged 10 and older with type 2 diabetes, based on a single-dose pharmacokinetic study in 18 children and modelling from adult data. Hypoglycaemia is the most common adverse reaction.

News about this drug

Also in the catalogue

Scales

Identifiers

INN
insulin icodec

Details

Status
Approved
Class
Once-weekly basal insulin analogue
Trade names
Awiqli

A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.